题名

消除C型肝炎最關鍵的一哩路：注射藥物族群的防治現況與建議

并列篇名

The most critical mile to eliminate hepatitis C: Current status and recommendations for the prevention and treatment of people who inject drugs

DOI

10.6288/TJPH.202210_41(5).PF05

作者

王聲昌(Sheng-Chang Wang)；林佩萱(Pei-Hsuan Lin)；鍾安妮(An-Nie Chung)；鍾宇筑(Yu-Ju Ella Chung)；陳為堅(Wei J. Chen)

关键词
期刊名称

台灣公共衛生雜誌

卷期/出版年月

41卷5期（2022 / 10 / 31）

页次

479 - 482

内容语文

繁體中文
主题分类 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 社會醫學
参考文献
  1. 吳慧敏, GH,楊雯雯, WW,劉嘉玲, CL(2021)。台灣2025年C肝消除的策略與進度。台灣衛誌，40，1-4。
    連結：
  2. Afdhal, N,Zeuzem, S,Kwo, P(2014).Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med,370,1889-1898.
  3. Chen, YC,Chen, CK,Lin, SK,Chiang, SC,Su, LW,Wang, LJ(2013).Health care service utilization and associated factors among heroin users in northern Taiwan.Addict Behav,38,2635-2638.
  4. Chevaliez, S,Wlassow, M,Volant, J(2020).Assessing molecular point-of-care testing and dried blood spot for hepatitis C virus screening in people who inject drugs.Open Forum Infect Dis,7,ofaa196.
  5. Degenhardt, L,Peacock, A,Colledge, S(2017).Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.Lancet Glob Health,5,e1192-e1207.
  6. Eckhardt, B,Kapadia, SN,Mateu-Gelabert, P(2022).Rapid treatment initiation for hepatitis C in young people who inject drugs: the seek, test, and rapid treatment randomized trial.Open Forum Infect Dis,9,ofac225.
  7. Ferenci, P,Bernstein, D,Lalezari, J(2014).ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.N Engl J Med,370,1983-1992.
  8. Freiman, JM,Tran, TM,Schumacher, SG(2016).Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis.Ann Intern Med,165,345-355.
  9. Heckathorn, DD(1997).Respondent-driven sampling: a new approach to the study of hidden populations.Soc Probl,44,174-199.
  10. Hsu, JT,Hsu, PI,Shie, CB(2022).Comparison of the efficacies of direct-acting antiviral treatment for HCV infection in people who inject drugs and non-drug users.Medicina,58,436.
  11. Hu, TH,Su, WW,Yang, CC(2021).Changhua-Integrated Program to Stop Hepatitis C Infection (CHIPS-C) of Taiwan.J Hepatol,75,S668.
  12. Lazarus, JV,Wiktor, S,Colombo, M,Thursz, M,EASL International Liver Foundation(2017).Micro-elimination - a path to global elimination of hepatitis C.J Hepatol,67,665-666.
  13. Ng, MH,Chou, JY,Chang, TJ(2013).High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan.Addict Behav,38,2089-2093.
  14. Platt, L,Minozzi, S,Reed, J(2018).Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane review and meta-analysis.Addiction,113,545-563.
  15. Radley, A,de Bruin, M,Inglis, SK(2020).Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.Lancet Gastroenterol Hepatol,5,809-818.
  16. Rapoud, D,Quillet, C,Pham, Minh, K(2020).Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).BMJ Open,10,e039234.
  17. Tai, CM,Huang, CK,Changchien, TC(2022).Collaborative referral model to achieve hepatitis C micro-elimination in methadone maintenance treatment patients during the COVID-19 pandemic.Viruses,14,1637.
  18. Trickey, A,Fraser, H,Lim, AG(2019).The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study.Lancet Gastroenterol Hepatol,4,435-444.
  19. Tuaillon, E,Mondain, AM,Meroueh, F(2010).Dried blood spot for hepatitis C virus serology and molecular testing.Hepatology,51,752-758.
  20. WHO(2016).Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis.Geneva:WHO.
  21. Williams, B,Howell, J,Doyle, J(2019).Point-of-care hepatitis C testing from needle and syringe programs: an Australian feasibility study.Int J Drug Policy,72,91-98.
  22. Wong, NS,Chan, DP,Chan, CP(2022).Point-of-care hepatitis C reflex testing and treatment referral in methadone clinic settings in Hong Kong -- a pilot study.IJID Reg,5,8-12.
  23. Wu, GH,Pwu, RF,Chen, SC(2018).Achieving hepatitis C elimination in Taiwan -- overcoming barriers by setting feasible strategies.J Formos Med Assoc,117,1044-1045.
  24. Yen, YF,Yen, MY,Su, LW(2012).Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan.BMC Public Health,12,1066.
  25. 國家消除C肝政策綱領編輯團隊=Taiwan National Hepatitis C Program Office(2019).2018-2025國家消除C肝政策綱領.台北=Taipei:衛生福利部=Ministry of Health and Welfare, R.O.C. (Taiwan).
  26. 衛生福利部：健保口服C肝新藥使用情形與治療成效。https://www.mohw.gov.tw/cp-4465-62953-1.html。引用2022/09/26。 Ministry of Health and Welfare, R.O.C. (Taiwan). Real-world utilization and effectiveness of DAAs in Taiwan. Available at: https://www.mohw.gov.tw/cp-4465-62953-1.html. Accessed September 26, 2022. [In Chinese]
print cancel